Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

The stock is up around 38% over the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
investora2z Member Profile
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Genentech: Tecentriq/Cotellic/Zelboraf Combo Study Meets Primary Endpoint Dow Jones News - 12/13/2019 7:37:00 AM
Genentech: Subcutaneous Perjeta/Herceptin Combo Comparable to IV Dow Jones News - 12/12/2019 11:44:00 AM
Novartis: FDA Accepts Xolair sBLA for Nasal Polyps Dow Jones News - 12/11/2019 6:37:00 AM
Roche Approves Proposals for Board and Executive Committee Dow Jones News - 12/9/2019 2:50:00 AM
Roche Extends Tender Offer for Spark Therapeutics Dow Jones News - 12/9/2019 2:16:00 AM
FDA Approves Marketing of Roche Diagnostics MRSA Diagnostic Test Dow Jones News - 12/5/2019 1:10:00 PM
Genentech: FDA Approves Tecentriq Plus Chemotherapy for Some Non-Small Cell Lung Cancer Dow Jones News - 12/3/2019 7:21:00 PM
Genentech Gets FDA Priority Review for Risdiplam for Spinal Muscular Atrophy Dow Jones News - 11/25/2019 7:36:00 AM
FDA Accepts Avastin Biosimilar BLA From Biogen, Samsung BioLogics Venture Dow Jones News - 11/19/2019 8:45:00 AM
New Hope in the Battle Against Ovarian Cancer NetworkNewsWire - 11/5/2019 8:45:00 AM
Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics NetworkNewsWire - 10/29/2019 8:45:00 AM
U.K.'s Competition Watchdog Opens Probe into Roche Takeover of Spark Therapeutics Dow Jones News - 10/22/2019 2:46:00 AM
Roche: Phase 3 Study of Tecentriq, Avastin Combination a Success Dow Jones News - 10/21/2019 1:44:00 AM
Roche Says Outlook Is Improving as Revenue Grows Dow Jones News - 10/16/2019 1:48:00 AM
Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive Dow Jones News - 9/30/2019 11:20:00 AM
Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders Dow Jones News - 9/27/2019 2:32:00 PM
Genentech Says Data Positive From Tecentriq Lung Cancer Study Dow Jones News - 9/27/2019 11:20:00 AM
U.K. Regulator to Probe Roche's Acquisition of Spark Therapeutics Dow Jones News - 9/25/2019 2:54:00 AM
Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers NetworkNewsWire - 9/24/2019 8:45:00 AM
Genentech Gets FDA Breakthrough Designation for Gazyva in Lupus Nephritis Dow Jones News - 9/18/2019 6:40:00 AM
Genentech Receives FDA Accelerated Approval for Cancer Treatment Dow Jones News - 8/15/2019 4:36:00 PM
Roche Extends Offer Period for Spark Therapeutics Dow Jones News - 7/31/2019 1:48:00 AM
Roche: CHMP Backs Tecentriq in Extensive-Stage Small-Cell Lung Cancer Dow Jones News - 7/26/2019 10:46:00 AM
Roche Sales Boosted by New Drug Pipeline -- Update Dow Jones News - 7/25/2019 4:14:00 AM
Roche 1st Half Profit, Sales Grew; Raises Full-Year Sales Guidance Dow Jones News - 7/25/2019 1:46:00 AM
investora2z   Thursday, 09/19/13 06:36:39 AM
Re: None
Post # of 138 
The stock is up around 38% over the last one year. Over the longer term also, the stock has done well with decent returns for the investors. It has been a bit volatile over the last few months, but is starting to look strong again. As mentioned in an article on Motley Fool, Roche is a good stock for investors looking for conservative growth. In the first half of fiscal 2013, its group sales rose 5%, and the core earnings per share climbed 12%. The HER2 franchise grew 11% to around $3.55 billion, accounting for 14% of the company's top line. It has been working with experimental companies like Inovio (INO). This could help it prepare for the patent expirations starting next year for Herceptin ($6.3 billion in sales in fiscal 2012). The new subcutaneous formulation of Herceptin which was recently approved in the EU is also likely to help make up for the loss. Roche's exclusive worldwide license deal with Inovio will support continuous research, development and commercialization of Inovio's SynCon technology vaccines for prostate cancer and Hepatitis B. The deal mainly gives Roche exposure to the high potential prostate cancer market and access to electroporation technique for administration of vaccines. This drug delivery technology is promising though the technology itself is still in the trials phase and will be subjected to regulatory approvals etc. As mentioned in an article on Trefis, there are other drug delivery technologies like the QuSomes of Biozone (BZNE). This technique (liposomal delivery of drugs) is also very promising with OPKO Health (OPK) having a licensing agreement with Biozone for testing / commercialization of QuSomes. Even QuSomes can find place in drug delivery for cancer treatments. Hopefully, the deal will help both Roche and Inovio in the long term.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist